SPATA2

Summary

SPATA2 (spermatogenesis associated 2, HGNC:14681) is a protein-coding gene on chromosome 20q13.13, encoding Spermatogenesis-associated protein 2 (Q9UM82). Bridging factor that mediates the recruitment of CYLD to the LUBAC complex, thereby regulating TNF-induced necroptosis.

Enables signaling receptor complex adaptor activity and ubiquitin-specific protease binding activity. Involved in several processes, including protein deubiquitination; regulation of necroptotic process; and regulation of tumor necrosis factor-mediated signaling pathway. Located in cytoplasm; fibrillar center; and nucleoplasm.

Source: NCBI Gene 9825 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 93 total
• MANE Select transcript: NM_006038

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14681
Approved symbol	SPATA2
Name	spermatogenesis associated 2
Location	20q13.13
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0757, PD1, tamo, PPP1R145
Ensembl gene	ENSG00000158480
Ensembl biotype	protein_coding
OMIM	607662
Entrez	9825

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 8 protein_coding

ENST00000289431, ENST00000422556, ENST00000857509, ENST00000857510, ENST00000857511, ENST00000939097, ENST00000939098, ENST00000949397

RefSeq mRNA: 2 — MANE Select: NM_006038 NM_001135773, NM_006038

CCDS: CCDS13422

Canonical transcript exons

ENST00000289431 — 3 exons

Exon	Start	End
ENSE00001039165	49915380	49915529
ENSE00001455895	49908155	49908592
ENSE00001886022	49903391	49906845

Expression profiles

Bgee: expression breadth ubiquitous, 253 present calls, max score 96.63.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.0694 / max 182.7254, expressed in 1801 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
187803	9.2788	1762
187804	6.0691	1728
187805	0.4480	199
187802	0.1237	47
187801	0.1034	33
187800	0.0464	25

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	96.63	gold quality
middle temporal gyrus	UBERON:0002771	95.29	gold quality
endothelial cell	CL:0000115	95.09	gold quality
oocyte	CL:0000023	93.66	gold quality
Brodmann (1909) area 23	UBERON:0013554	90.67	gold quality
primary visual cortex	UBERON:0002436	88.67	gold quality
right frontal lobe	UBERON:0002810	87.04	gold quality
prefrontal cortex	UBERON:0000451	86.94	gold quality
Brodmann (1909) area 9	UBERON:0013540	86.58	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	86.53	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	85.68	gold quality
frontal cortex	UBERON:0001870	85.33	gold quality
caudate nucleus	UBERON:0001873	85.33	gold quality
neocortex	UBERON:0001950	85.02	gold quality
inferior olivary complex	UBERON:0002127	84.60	gold quality
putamen	UBERON:0001874	84.58	gold quality
cerebral cortex	UBERON:0000956	84.37	gold quality
spinal cord	UBERON:0002240	84.30	gold quality
cingulate cortex	UBERON:0003027	84.28	gold quality
nucleus accumbens	UBERON:0001882	84.14	gold quality
anterior cingulate cortex	UBERON:0009835	84.13	gold quality
superior frontal gyrus	UBERON:0002661	83.96	gold quality
telencephalon	UBERON:0001893	83.80	gold quality
occipital lobe	UBERON:0002021	83.80	gold quality
buccal mucosa cell	CL:0002336	83.77	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	83.41	gold quality
right hemisphere of cerebellum	UBERON:0014890	83.19	gold quality
gastrocnemius	UBERON:0001388	83.08	gold quality
entorhinal cortex	UBERON:0002728	82.97	gold quality
forebrain	UBERON:0001890	82.80	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.96

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ESR1

miRNA regulators (miRDB)

94 targeting SPATA2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-551B-5P	99.96	71.28	3493
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-3912-5P	99.95	66.11	925
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-4760-3P	99.93	70.50	2385
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-130A-3P	99.90	73.31	1861

Literature-anchored findings (GeneRIF, showing 10)

• cloning and base sequence of the promoter region (PMID:12531478)
• disappearance of TLD epitope reactivity from an otherwise stable EBV-specific response reflects selective loss of cognate antigen restimulation, not IL-7-dependent signals, and is immediately preceded by PD-1 upregulation to unprecedented levels. (PMID:19605492)
• Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. (PMID:20385810)
• PD-L1 is highly expressed in tumours rather than tumour-free lymph nodes, which is closely correlated with the impairment of IFN-gamma production of tumour-infiltrating T-cells. (PMID:25093496)
• The aim of this study was to investigate whether the HCP5, TNIP1, TNFAIP3, SPATA2 and COG6 genes were genetic risk factors for psoriasis in Chinese population. (PMID:25264125)
• The predicted PUB domain in the N-terminus of SPATA2 interacts with the USP domain of CYLD and SPATA2 is required for recruitment of CYLD to the TNF-alpha receptor-associated signaling complexes. (PMID:27307491)
• this study identifies SPATA2 as an important factor in the TNF signaling pathway with a substantial role for the effects mediated by the cytokine. (PMID:27458237)
• SPATA2 has been described as a previously unrecognized factor in the linear ubiquitin chain assembly complex-dependent signaling pathways that serves as an adaptor between HOIP and CYLD, thereby enabling recruitment of CYLD to signaling complexes. (PMID:27545878)
• The data reveal SPATA2 as a high-affinity binding partner of CYLD and HOIP, and a regulatory component of linear ubiquitin chain assembly complex-mediated NF-kappaB signaling. (PMID:27591049)
• A role of SPATA2 in tumorigenesis. (PMID:30697874)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	spata2	ENSDARG00000063250
mus_musculus	Spata2	ENSMUSG00000047030
rattus_norvegicus	Spata2	ENSRNOG00000009207
drosophila_melanogaster	tamo	FBGN0041582

Paralogs (1): SPATA2L (ENSG00000158792)

Protein

Protein identifiers

Spermatogenesis-associated protein 2 — Q9UM82 (reviewed: Q9UM82)

All UniProt accessions (1): Q9UM82

UniProt curated annotations — full annotation on UniProt →

Function. Bridging factor that mediates the recruitment of CYLD to the LUBAC complex, thereby regulating TNF-induced necroptosis. Acts as a direct binding intermediate that bridges RNF31/HOIP, the catalytic subunit of the LUBAC complex, and the deubiquitinase (CYLD), thereby recruiting CYLD to the TNF-R1 signaling complex (TNF-RSC). Required to activate the ‘Met-1’- (linear) and ‘Lys-63’-linked deubiquitinase activities of CYLD. Controls the kinase activity of RIPK1 and TNF-induced necroptosis by promoting ‘Met-1’-linked deubiquitination of RIPK1 by CYLD.

Subunit / interactions. Interacts (via the PIM motif) with RNF31/HOIP (via the PUB domain); the interaction is direct. Interacts (via the PUB domain) with CYLD; the interaction is direct.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Present at high level in Sertoli cells, but not detected in spermatogenic cells (at protein level). Low expression in spleen, thymus and prostate.

Similarity. Belongs to the SPATA2 family.

RefSeq proteins (2): NP_001129245, NP_006029* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR048839	SPATA2_PUB-like	Domain

Pfam: PF21388

UniProt features (32 total): helix 12, mutagenesis site 6, strand 4, region of interest 2, turn 2, chain 1, domain 1, sequence conflict 1, short sequence motif 1, modified residue 1, sequence variant 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
5LJM	X-RAY DIFFRACTION	1.45
5LJN	X-RAY DIFFRACTION	2.7

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UM82-F1	68.71	0.32

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 253

Mutagenesis-validated functional residues (6):

Position	Phenotype
114	reduced interaction with cyld.
115	reduced interaction with cyld.
338	strongly reduced interaction with rnf31/hoip.
94	weak or no effect on interaction with cyld.
98	weak or no effect on interaction with cyld.
108	abolished interaction with cyld.

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-5357786	TNFR1-induced proapoptotic signaling
R-HSA-5357905	Regulation of TNFR1 signaling
R-HSA-5357956	TNFR1-induced NF-kappa-B signaling pathway
R-HSA-162582	Signal Transduction
R-HSA-73887	Death Receptor Signaling
R-HSA-75893	TNF signaling

MSigDB gene sets: 184 (showing top): GOBP_INFLAMMATORY_RESPONSE, GOBP_RESPONSE_TO_PEPTIDE, GOBP_MALE_GAMETE_GENERATION, GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_REMOVAL, MORF_RAD51L3, MODULE_205, GOBP_REPRODUCTIVE_SYSTEM_DEVELOPMENT, GOBP_REGULATION_OF_RESPONSE_TO_STRESS, GOBP_TUMOR_NECROSIS_FACTOR_MEDIATED_SIGNALING_PATHWAY, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP, GOBP_SEX_DIFFERENTIATION, GOBP_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS, GOBP_REGULATION_OF_TUMOR_NECROSIS_FACTOR_MEDIATED_SIGNALING_PATHWAY, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION

GO Biological Process (9): spermatogenesis (GO:0007283), regulation of tumor necrosis factor-mediated signaling pathway (GO:0010803), regulation of inflammatory response (GO:0050727), regulation of necroptotic process (GO:0060544), necroptotic process (GO:0070266), protein K63-linked deubiquitination (GO:0070536), seminiferous tubule development (GO:0072520), protein linear deubiquitination (GO:1990108), programmed cell death (GO:0012501)

GO Molecular Function (4): signaling receptor complex adaptor activity (GO:0030159), protein-containing complex binding (GO:0044877), ubiquitin-specific protease binding (GO:1990381), protein binding (GO:0005515)

GO Cellular Component (5): fibrillar center (GO:0001650), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
TNF signaling	3
Signal Transduction	1
Death Receptor Signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
protein deubiquitination	2
binding	2
developmental process involved in reproduction	1
male gamete generation	1
regulation of cytokine-mediated signaling pathway	1
tumor necrosis factor-mediated signaling pathway	1
inflammatory response	1
regulation of defense response	1
regulation of response to external stimulus	1
regulation of programmed necrotic cell death	1
necroptotic process	1
programmed necrotic cell death	1
male gonad development	1
tube development	1
reproductive structure development	1
signal transduction	1
cell death	1
signaling receptor binding	1
signaling adaptor activity	1
protease binding	1
nucleolus	1
nuclear lumen	1
intracellular anatomical structure	1
cytoplasm	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

420 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SPATA2	CYLD	Q9NQC7	880
SPATA2	RNF31	Q96EP0	778
SPATA2	RBCK1	Q9BYM8	619
SPATA2	OTULIN	Q96BN8	609
SPATA2	SHARPIN	Q9H0F6	571
SPATA2	TRADD	Q15628	556
SPATA2	TNF	P01375	487
SPATA2	RNF114	Q9Y508	430
SPATA2	ZUP1	Q96AP4	412
SPATA2	NGLY1	Q96IV0	371
SPATA2	RIPK1	Q13546	368
SPATA2	TNFRSF1A	P19438	359
SPATA2	ATP6V1G2	O95670	357
SPATA2	PHF20	Q9BVI0	355
SPATA2	BBOX1	O75936	324

IntAct

89 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
TRIM27	SPATA2	psi-mi:“MI:0915”(physical association)	0.670
GOLGA2	SPATA2	psi-mi:“MI:0915”(physical association)	0.670
SPATA2	GOLGA2	psi-mi:“MI:0915”(physical association)	0.670
SPATA2	LZTS2	psi-mi:“MI:0915”(physical association)	0.560
SPATA2	MAD1L1	psi-mi:“MI:0915”(physical association)	0.560
LZTS2	SPATA2	psi-mi:“MI:0915”(physical association)	0.560
SPATA2	ZNF835	psi-mi:“MI:0915”(physical association)	0.560
ATP6V1H	SPATA2	psi-mi:“MI:0915”(physical association)	0.560
KIFC3	SPATA2	psi-mi:“MI:0915”(physical association)	0.560
KAT5	SPATA2	psi-mi:“MI:0915”(physical association)	0.560
CCDC102B	SPATA2	psi-mi:“MI:0915”(physical association)	0.560
C2CD6	SPATA2	psi-mi:“MI:0915”(physical association)	0.560
TNIP1	SPATA2	psi-mi:“MI:0915”(physical association)	0.560
TBC1D22B	SPATA2	psi-mi:“MI:0915”(physical association)	0.560
SPATA2	ANKRD11	psi-mi:“MI:0915”(physical association)	0.560
LENG1	SPATA2	psi-mi:“MI:0915”(physical association)	0.560
EFHC1	SPATA2	psi-mi:“MI:0915”(physical association)	0.560
GPANK1	SPATA2	psi-mi:“MI:0915”(physical association)	0.560
CYLD	SPATA2	psi-mi:“MI:0915”(physical association)	0.560
SPATA2	GFAP	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (145): SPATA2 (Two-hybrid), SPATA2 (Two-hybrid), SPATA2 (Two-hybrid), LZTS2 (Two-hybrid), SPATA2 (Affinity Capture-MS), SPATA2 (Two-hybrid), SPATA2 (Two-hybrid), CEP72 (Two-hybrid), SPATA2 (Proximity Label-MS), SPATA2 (Proximity Label-MS), SPATA2 (Proximity Label-MS), SPATA2 (Proximity Label-MS), SPATA2 (Proximity Label-MS), SPATA2 (Proximity Label-MS), SPATA2 (Affinity Capture-MS)

ESM2 similar proteins: A0A8M9QN10, A0FGR0, A1L3I3, A7LKB2, B1AZP2, E9Q9W7, F1QCY8, O08576, O43147, O54834, P0C6P5, P51111, P59729, P97433, P97839, Q17QK1, Q2NKQ1, Q2TAL5, Q2THW7, Q2THW9, Q2THX1, Q59EK9, Q5R565, Q5R838, Q5RD34, Q5U3W3, Q5U464, Q5VUB5, Q5Y5T5, Q66HP6, Q6BCB4, Q6INH1, Q6NXJ0, Q75N33, Q75NY9, Q80Y56, Q8BPQ7, Q8CI12, Q8K004, Q8VDZ4

Diamond homologs: F1QCY8, Q0IIA6, Q66HP6, Q8BNN1, Q8IUW3, Q8K004, Q9UM82, Q9W1A4

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 59 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Loss of Nlp from mitotic centrosomes	7	27.1×	9e-07
Loss of proteins required for interphase microtubule organization from the centrosome	7	27.1×	9e-07
AURKA Activation by TPX2	7	26.0×	9e-07
Recruitment of mitotic centrosome proteins and complexes	7	23.2×	2e-06
Regulation of PLK1 Activity at G2/M Transition	7	21.7×	2e-06
Recruitment of NuMA to mitotic centrosomes	7	19.9×	3e-06
Anchoring of the basal body to the plasma membrane	7	19.3×	3e-06

Disease & clinical

Clinical variants and AI predictions

ClinVar

93 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	86
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

558 predictions. Top by Δscore:

Variant	Effect	Δscore
20:49915375:CTCA:C	donor_loss	1.0000
20:49915376:TCA:T	donor_loss	1.0000
20:49915377:CA:C	donor_loss	1.0000
20:49915378:AC:A	donor_gain	1.0000
20:49915379:C:CA	donor_loss	1.0000
20:49915379:CC:C	donor_gain	1.0000
20:49906846:C:CC	acceptor_gain	0.9900
20:49908149:CCTCA:C	donor_loss	0.9900
20:49908150:CTCAC:C	donor_loss	0.9900
20:49908151:TCAC:T	donor_loss	0.9900
20:49908152:CA:C	donor_loss	0.9900
20:49908153:A:C	donor_loss	0.9900
20:49908154:C:CG	donor_loss	0.9900
20:49908591:CT:C	acceptor_gain	0.9900
20:49915373:CACT:C	donor_loss	0.9900
20:49915374:ACTC:A	donor_loss	0.9900
20:49915378:A:AC	donor_gain	0.9900
20:49915379:C:CC	donor_gain	0.9900
20:49906841:TAGGT:T	acceptor_gain	0.9800
20:49906860:G:GC	acceptor_gain	0.9800
20:49908153:A:AC	donor_gain	0.9800
20:49908154:C:CC	donor_gain	0.9800
20:49908588:GTGCT:G	acceptor_gain	0.9800
20:49908589:TGCT:T	acceptor_gain	0.9800
20:49908593:C:CC	acceptor_gain	0.9800
20:49906814:T:C	acceptor_gain	0.9700
20:49906819:A:C	acceptor_gain	0.9700
20:49906843:GGT:G	acceptor_gain	0.9700
20:49906843:GGTCT:G	acceptor_loss	0.9700
20:49906845:TCTA:T	acceptor_loss	0.9700

AlphaMissense

3373 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:49905768:A:G	C472R	0.998
20:49905804:A:G	C460R	0.998
20:49905735:A:G	C483R	0.997
20:49905803:C:G	C460S	0.997
20:49905804:A:T	C460S	0.997
20:49908181:A:G	W104R	0.997
20:49908181:A:T	W104R	0.997
20:49908195:A:G	L99P	0.997
20:49905733:G:C	C483W	0.996
20:49905744:A:G	C480R	0.996
20:49905759:A:G	C475R	0.996
20:49905766:G:C	C472W	0.996
20:49905795:A:G	C463R	0.996
20:49906592:C:G	R197P	0.996
20:49906593:G:T	R197S	0.996
20:49906676:G:T	A169D	0.996
20:49906685:A:G	L166P	0.996
20:49906763:T:G	Y140S	0.996
20:49906764:A:C	Y140D	0.996
20:49908179:C:A	W104C	0.996
20:49908179:C:G	W104C	0.996
20:49908308:G:C	F61L	0.996
20:49908308:G:T	F61L	0.996
20:49908310:A:G	F61L	0.996
20:49905794:C:G	C463S	0.995
20:49905795:A:T	C463S	0.995
20:49905802:A:C	C460W	0.995
20:49906677:C:G	A169P	0.995
20:49906817:A:T	V122D	0.995
20:49908159:A:T	I111N	0.995

dbSNP variants (sampled 300 via entrez): RS1000364560 (20:49904838 ATATT>A), RS1000421471 (20:49904720 G>A), RS1000511776 (20:49914707 C>T), RS1000614847 (20:49915538 C>A,T), RS1000972951 (20:49905895 C>G,T), RS1001320337 (20:49905707 C>A,G), RS1001500367 (20:49911905 T>C), RS1001521148 (20:49917504 T>C), RS1001886139 (20:49914445 C>A), RS1001990008 (20:49903267 G>A), RS1001991168 (20:49908585 G>A,C,T), RS1002248841 (20:49908162 C>T), RS1002402397 (20:49914045 A>C), RS1002450371 (20:49913294 T>C), RS1002499889 (20:49910421 T>C)

Disease associations

OMIM: gene MIM:607662 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST000165_1	Psoriasis	1.000000e-08
GCST000834_7	Psoriasis	2.000000e-07
GCST002738_8	Psoriasis	3.000000e-09
GCST003876_14	Gut microbiota (beta diversity)	5.000000e-08
GCST005194_202	Coronary artery disease	1.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007874	gut microbiome measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, affects expression	3
Arsenic	affects methylation, affects cotreatment, increases abundance, increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	decreases phosphorylation	1
bisphenol F	affects cotreatment, increases expression	1
dicrotophos	increases expression	1
lasiocarpine	decreases expression	1
triphenyl phosphate	affects expression	1
cypermethrin	increases expression	1
sodium arsenite	affects cotreatment, increases abundance, increases expression	1
butyraldehyde	decreases expression	1
manganese chloride	affects cotreatment, increases abundance, increases expression	1
coumarin	affects phosphorylation	1
monomethylarsonous acid	increases expression	1
dimethylarsinous acid	increases expression	1
Sunitinib	increases expression	1
Leflunomide	decreases expression	1
Acetaminophen	increases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	decreases methylation	1
Dexamethasone	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Gold	affects binding, decreases expression	1
Indomethacin	affects cotreatment, increases expression	1
Manganese	affects cotreatment, increases abundance, increases expression	1
Polyethyleneimine	affects binding, decreases expression	1
Smoke	decreases expression	1
Tamoxifen	increases expression	1
Thimerosal	decreases expression	1
Tobacco Smoke Pollution	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.